Literature DB >> 1770068

Misoprostol--a logical therapeutic approach to gastroduodenal mucosal injury induced by non-steroidal anti-inflammatory drugs?

G C Fenn1, G C Robinson.   

Abstract

Misoprostol is a synthetic analogue of naturally occurring prostaglandin E1. The basis of the damaging actions of non-steroidal anti-inflammatory drugs (NSAIDs) on the gastrointestinal (GI) tract is believed to be a consequence of two events: a direct damaging action on mucosal integrity and depletion of endogenous mucosal prostaglandins (PGs). Due to the latter effect, and because current evidence indicates that PGs play an important role in maintaining the integrity of the GI tract, misoprostol has been developed as a logical therapy to prevent and heal gastric and duodenal damage caused by NSAIDs. The purpose of this review is to consider the need for such a therapy, to describe its pharmaceutical development, to review its pharmacology and to review its efficacy compared with other available agents.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1770068     DOI: 10.1111/j.1365-2710.1991.tb00330.x

Source DB:  PubMed          Journal:  J Clin Pharm Ther        ISSN: 0269-4727            Impact factor:   2.512


  11 in total

Review 1.  Nonsteroidal anti-inflammatory drugs and chondroprotection. A review of the evidence.

Authors:  P Ghosh
Journal:  Drugs       Date:  1993-11       Impact factor: 9.546

Review 2.  Misoprostol: pharmacoeconomics of its use as prophylaxis against gastroduodenal damage induced by nonsteroidal anti-inflammatory drugs.

Authors:  L B Barradell; R Whittington; P Benfield
Journal:  Pharmacoeconomics       Date:  1993-02       Impact factor: 4.981

3.  NSAIDS in the postoperative period. Don't dismiss gastric erosion.

Authors:  G C Fenn
Journal:  BMJ       Date:  1993-07-24

4.  A perspective on iron deficiency anaemia.

Authors:  J M Sayer; R G Long
Journal:  Gut       Date:  1993-10       Impact factor: 23.059

5.  Pharmacokinetics of nocloprost in human volunteers and its relation to dose.

Authors:  U Tüber; M Brudny-Klöppel; U Jakobs; C Madetzki; M Mahler
Journal:  Eur J Clin Pharmacol       Date:  1993       Impact factor: 2.953

Review 6.  Therapy and prevention of gastric ulcer.

Authors:  C B Lamers; I Biemond; A A Masclee; R A Veenendaal
Journal:  Yale J Biol Med       Date:  1996 May-Jun

Review 7.  Nonsteroidal anti-inflammatory drugs in perisurgical pain management. Mechanisms of action and rationale for optimum use.

Authors:  J Cashman; G McAnulty
Journal:  Drugs       Date:  1995-01       Impact factor: 9.546

8.  Experience with misoprostol therapy for NSAID gastropathy in children.

Authors:  M Gazarian; M Berkovitch; G Koren; E D Silverman; R M Laxer
Journal:  Ann Rheum Dis       Date:  1995-04       Impact factor: 19.103

Review 9.  Diclofenac/misoprostol. A review of its pharmacology and therapeutic efficacy in painful inflammatory conditions.

Authors:  R Davis; Y E Yarker; K L Goa
Journal:  Drugs Aging       Date:  1995-11       Impact factor: 3.923

Review 10.  Omeprazole. An update of its pharmacology and therapeutic use in acid-related disorders.

Authors:  M I Wilde; D McTavish
Journal:  Drugs       Date:  1994-07       Impact factor: 9.546

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.